Stephen J. DiPalma's most recent trade in Inozyme Pharma Inc was a trade of 15,000 Stock option (Right to Buy) done . Disclosure was reported to the exchange on May 17, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inozyme Pharma Inc | Stephen J. DiPalma | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 15,000 | 15,000 | - | - | Stock option (Right to Buy) |